Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2491 to 2505 of 9102 results

  1. Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults [ID1297]

    Technology appraisal Reference number: TA714 Published:  14 July 2021

    Technology appraisal guidance
    In development

  2. Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]

    In development Reference number: GID-TA11422 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  3. Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over [ID6542]

    In development Reference number: GID-TA11525 Expected publication date:  10 February 2027

    Technology appraisal guidance
    In development

  4. Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women [ID1401]

    In development Reference number: GID-TA10326 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]

    In development Reference number: GID-TA11429 Expected publication date:  09 September 2026

    Technology appraisal guidance
    In development

  6. Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis [ID6351]

    In development Reference number: GID-TA11333 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over [ID6557]

    In development Reference number: GID-TA11693 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Blarcamesine for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6679]

    Awaiting development Reference number: GID-TA11717 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Denosumab biosimilar for Giant cell-rich tumours of bone or Skeletal events in bone malignancies [TSID12150]

    Awaiting development Reference number: GID-TA11783 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Acalabrutinib with R-CHOP for untreated non-germinal centre B-cell diffuse large B-cell lymphoma [ID6614]

    Awaiting development Reference number: GID-TA11811 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Alectinib for treating unresectable locally advanced non-small-cell lung cancer [GID-TA12468]

    Awaiting development Reference number: GID-TA12468 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Technologies to improve detection of endometrial cancer

    Awaiting development Reference number: GID-HTG10173 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  13. Dostarlimab for untreated locally advanced rectal cancer with high microsatellite instability or mismatch repair deficiency [ID6747]

    Awaiting development Reference number: GID-TA11972 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines [ID6356]

    In development Reference number: GID-TA11416 Expected publication date:  22 October 2026

    Technology appraisal guidance
    In development

  15. Fenfluramine for treating seizures caused by CDKL5 deficiency disorder in people 1 year and over [ID6740]

    Awaiting development Reference number: GID-TA11966 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development